Inhibition of Seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers.
about
Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha1A-blocker administrationSilodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptabilityThe drug treatment of premature ejaculationEjaculatory dysfunction in the treatment of lower urinary tract symptomsThe pathophysiology of delayed ejaculationEmerging and investigational drugs for premature ejaculationSilodosin for benign prostatic hyperplasia.A systematic review of the correlates and management of nonpremature ejaculatory dysfunction in heterosexual menBenign prostatic hyperplasia: from bench to clinicA meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH.Silodosin in the treatment of benign prostatic hyperplasiaSafety and efficacy of silodosin for the treatment of benign prostatic hyperplasiaClinical Background of Patients with Sperm in Their Urinary Sediment.Physiological and pharmacological aspects of the vas deferens-an updateMeasurement of benign prostatic hyperplasia treatment effects on male sexual function.Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.Update on the sexual impact of treatment for benign prostatic hyperplasia.Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.Comparison of alpha blockers in treatment of premature ejaculation: a pilot clinical trial.A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia.Orgasmic Dysfunction after Radical Prostatectomy.Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH.Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.Cardiovascular/Pulmonary Medications and Male Reproduction.Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.FDA-approved drugs that are spermatotoxic in animals and the utility of animal testing for human risk prediction.Silodosin versus naftopidil in the treatment of premature ejaculation: A prospective multicenter trial.Effects of silodosin on sexual function - realistic picture from the everyday clinical practice.Silodosin improved spontaneous ejaculation induced by mental strain.Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function.
P2860
Q24632336-42DEC660-CD0E-462A-B0AD-AE6212E7EB30Q26823762-68CD374A-522E-4F58-B761-FE13B71C7093Q28072609-B8535F13-7311-488D-8D6C-9B1062A355DFQ28073775-7AA7ED8F-CD90-4230-873C-A1727477168FQ28074466-6D34217E-3CBD-489F-8699-2827F3024D68Q28078002-3EFEE467-F93C-4C3F-9218-EB1D59D25793Q33158241-A22569A6-026C-466F-8833-0E865987AAAEQ34038361-DE4F3DA2-B537-484B-908B-06FAD16B05D4Q34216723-1FFD23EE-2417-4E0B-8DBE-FB79F1139786Q34417223-4092CFED-1E2C-4F5C-B6AD-5680D9F4B933Q34625490-5D6D1EC6-EBD2-49DD-B66D-52E7C2CA3392Q34630995-704DC553-11EA-4AED-B0F3-8CE17C3A4BCDQ35770400-06EF3E05-116D-4FA4-9718-D10F325AF135Q37111681-DAB5108C-DF0B-4180-A98B-7BD86B4917ECQ37523227-B2EE2413-B0F5-48A0-8020-EA8574B199EAQ37875062-EFE94B88-05F5-4B6A-AC1B-7DA58FEACE92Q38038271-FDE9A51A-AB8D-458B-B4EA-0ACF663E84F6Q38052091-D4766E72-3B81-4799-9544-9F2FD2D46314Q38239520-95CD4BF7-0E8A-43D1-A776-D3FED6A6280AQ38257330-AC9D33D0-B96C-49CF-B402-C2DAC3D5FAC4Q38485721-07A7E9FA-A03A-4182-B56D-A758767EDC77Q38811490-9B417C5F-2E1E-413A-9033-8A295C3F71E5Q41922883-23CD280B-131E-4928-AF8D-F842CB79482CQ42927362-4E279181-D34D-42A9-879E-AAC09BDC810BQ46236880-0C792CB1-D672-46A8-9795-AE3D33426D9BQ47434739-15DFFC02-CBEF-44AF-BDD7-62C90189E34CQ47731603-844D30BF-FB15-4001-8D2B-116C73D97D2AQ48631981-0BA65381-FCFF-4BD2-AE4C-19F5A8B07FE0Q48935484-994D1EBB-C42D-4B69-92E3-04244C822256Q50653584-4D38E124-D59E-4145-8F83-A5E40ED43234Q53163585-2501916B-02F3-41C1-9888-F7A2D3A5AFB5
P2860
Inhibition of Seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Inhibition of Seminal emission ...... -blocker in normal volunteers.
@ast
Inhibition of Seminal emission ...... -blocker in normal volunteers.
@en
Inhibition of Seminal emission ...... -blocker in normal volunteers.
@nl
type
label
Inhibition of Seminal emission ...... -blocker in normal volunteers.
@ast
Inhibition of Seminal emission ...... -blocker in normal volunteers.
@en
Inhibition of Seminal emission ...... -blocker in normal volunteers.
@nl
prefLabel
Inhibition of Seminal emission ...... -blocker in normal volunteers.
@ast
Inhibition of Seminal emission ...... -blocker in normal volunteers.
@en
Inhibition of Seminal emission ...... -blocker in normal volunteers.
@nl
P2093
P1476
Inhibition of Seminal emission ...... -blocker in normal volunteers.
@en
P2093
Ko Kobayashi
Kohei Hashimoto
Naoki Itoh
Naoya Masumori
Ryuichi Kato
Shin-ichi Hisasue
Taiji Tsukamoto
P304
P356
10.1111/J.1743-6109.2008.00779.X
P577
2007-04-09T00:00:00Z